MOH — authorised 16 March 2005
- Marketing authorisation holder: FUJISAWA HLTHCARE
- Status: likely_approved
MOH authorised Mycamine on 16 March 2005
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 16 March 2005.
FUJISAWA HLTHCARE holds the Israeli marketing authorisation.